Announcements Trials

Browse Landscape

Phase

Phase 2 3 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, T-Cell 1

Interventions

Cisplatin 98 Gemcitabine 66 Paclitaxel 62 Carboplatin 60 Fluorouracil 59 Docetaxel 59 Capecitabine 59 Oxaliplatin 56 Cyclophosphamide 54 Radiotherapy 50 Drug Therapy 46 Bevacizumab 38 pembrolizumab 35 Dexamethasone 33 Magnetic Resonance Spectroscopy 32 Leucovorin 32 Doxorubicin 31 Cytarabine 27 Etoposide 26 Pemetrexed 25 Nivolumab 24 Methotrexate 24 Radiation 20 venetoclax 18 Vincristine 18 apatinib 17 Trastuzumab 17 Rituximab 17 Prednisone 17 Letrozole 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × zanolimumab × Clear all

NCT00877656 2024-03-18

HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma

Emergent BioSolutions

Phase 2/3 Completed

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡